Related Experiment Video
Updated: Jun 4, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
[Cardiorenal syndrome and its pathophysiological implications]
Francisca Dias De Castro1, Paulo Castro Chaves, Adelino F Leite-Moreira
1Serviço de Fisiologia, Faculdade de Medicina do Porto, Porto, Portugal.
Insights
Cardiorenal syndrome involves heart and kidney dysfunction, increasing patient mortality. A new classification (Types I-V) aids diagnosis and treatment of this growing condition.
Area of Science:
- Cardiology
- Nephrology
- Pathophysiology
Context:
- Cardiorenal syndrome is a complex condition where heart and kidney dysfunction exacerbate each other.
- Increasing longevity contributes to a rise in cardiorenal syndrome incidence.
- This syndrome leads to significantly higher morbidity and mortality rates.
Purpose:
- To review recent advancements in understanding cardiorenal syndrome.
- To propose a novel classification system (Types I-V) for better comprehension and systematization.
- To highlight the role of biomarkers in early diagnosis and risk stratification.
Summary:
- Cardiorenal syndrome (CRS) involves combined cardiac and renal dysfunction.
- A proposed classification includes Type I (acute cardiac worsening -> AKI), Type II (chronic cardiac dysfunction -> CKD), Type III (acute renal worsening -> cardiac dysfunction), Type IV (CKD -> cardiac dysfunction), and Type V (systemic disease affecting both organs).
- Biomarkers offer potential for early diagnosis and management.
Impact:
- The proposed classification aids in identifying underlying abnormalities.
- It facilitates the establishment of effective therapeutic strategies for cardiorenal syndrome.
- Early diagnosis and stratification using biomarkers can improve patient outcomes.
Abstract:
Cardiorenal syndrome is a pathophysiological condition in which combined cardiac and renal dysfunction amplifies individual organs failure progression. Therefore, morbidity and mortality is higher in this group patients. Its incidence has increased due to increased longevity and because patients survive more years with cardiac and/or renal dysfunction. The aim of the present paper is the revision of the most recent advances in this area. For a better comprehension and systematization of this syndrome it is suggested a classification in various subtypes (I-V). Type I reflects an abrupt worsening of cardiac function leading to acute kidney injury. Type II results from chronic abnormalities in cardiac function (chronic heart failure) causing progressive and potentially irreversible kidney disease. Type III consists of an abrupt worsening of renal function (acute kidney lesion) causing acute cardiac dysfunction (heart failure, arrhythmia or ischemia). Type IV describes a state of chronic kidney disease contributing to decrease cardiac function, ventricular hypertrophy, and/or increased risk of adverse cardiovascular events. Type V reflects a systemic condition causing both: cardiac and renal dysfunction. The clinical use of recently identified biomarkers can be an additional tool in the early diagnosis and stratification of this syndrome. This classification can be particularly useful in the identification of underlying abnormalities and in the establishment of an effective therapeutic approach.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
